S100A9 and pneumococcal meningitis: Evidence suggests that paquinimod, an MRP14-inhibitor, and an anti-HMGB1 antibody can improve clinical outcome as adjunctive therapeutics in a mouse model of pneumococcal meningitis, and adjunctive inhibition of MRP14 or HMGB1 reduces mortality in mice with pneumococcal meningitis.